First Choice Healthcare Solutions (FCHS) 10-Q14 Nov 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2014	Nov. 10, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'First Choice Healthcare Solutions, Inc.	'
Entity Central Index Key	'0001416876	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'FCHS	'
Entity Common Stock, Shares Outstanding	'	17,713,804
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash	$137,018	$739,158
Cash-restricted	340,672	256,246
Accounts receivable, net	2,114,525	1,272,155
Prepaid and other current assets	264,440	140,580
Capitalized financing costs, current portion	57,348	57,348
Total current assets	2,914,003	2,465,487
Property, plant and equipment, net of accumulated depreciation of $2,341,377 and $1,959,127	8,425,452	8,662,057
Other assets	'	'
Capitalized financing costs, long term portion	69,483	131,540
Patient list, net of accumulated amortization of $50,000 and $35,000	250,000	265,000
Patents, net of amortization of $14,325	272,175	286,500
Deposits	2,713	2,713
Total other assets	594,371	685,753
Total assets	11,933,826	11,813,297
Current liabilities	'	'
Accounts payable and accrued expenses	1,078,142	459,000
Stock based payable	28,750	166,340
Advances	50,000	0
Line of credit, short term	1,202,000	800,000
Convertible note payable, short term portion	1,611,626	0
Notes payable, current portion	781,162	743,787
Unearned revenue	42,099	74,934
Total current liabilities	4,793,779	2,244,061
Long term debt:	'	'
Deposits held	72,901	72,901
Convertible note payable, long term portion	537,209	2,347,403
Notes payable, long term portion	8,328,870	8,935,473
Total long term debt	8,938,980	11,355,777
Total liabilities	13,732,759	13,599,838
Stockholders' deficit	'	'
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Nil issued and outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 17,688,804 and 16,747,248 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	17,689	16,747
Additional paid in capital	12,406,205	11,560,249
Accumulated deficit	-14,222,827	-13,363,537
Total stockholders' deficit	-1,798,933	-1,786,541
Total liabilities and stockholders' deficit	$11,933,826	$11,813,297

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accumulated depreciation of property plant and equipment (in dollars)	$2,341,377	$1,959,127
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,688,804	16,747,248
Common stock, shares outstanding	17,688,804	16,747,248
Patents [Member]	'	'
Accumulated amortization (in dollars)	14,325	0
Patient List [Member]	'	'
Accumulated amortization (in dollars)	$50,000	$35,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Patient service revenue	$1,917,597	$1,395,610	$5,814,140	$3,739,435
Provision for bad debts	-290,440	0	-365,712	0
Net patient service revenue less provision for bad debts	1,627,157	1,395,610	5,448,428	3,739,435
Rental revenue	263,888	259,120	784,534	786,546
Total Revenue	1,891,045	1,654,730	6,232,962	4,525,981
Operating expenses:	'	'	'	'
Salaries & benefits	925,513	735,888	3,081,840	2,000,436
Other operating expenses	407,699	353,034	1,264,046	965,923
General & administrative	548,635	298,566	1,623,755	898,910
Depreciation and amortization	150,084	124,378	411,575	373,803
Total operating expenses	2,031,931	1,511,866	6,381,216	4,239,072
Net (loss) income from operations	-140,886	142,864	-148,254	286,909
Other income (expense):	'	'	'	'
Miscellaneous income	750	750	2,250	2,313
Gain on change in fair value of derivative liability	0	-1,631	0	187,351
Amortization Financing costs	-20,686	-22,802	-62,058	-51,477
Interest expense, net	-214,798	-302,590	-651,228	-983,966
Total other income (expense)	-234,734	-326,273	-711,036	-845,779
Net loss before provision for income taxes	-375,620	-183,409	-859,290	-558,870
Income taxes (benefit)	0	0	0	0
NET LOSS	($375,620)	($183,409)	($859,290)	($558,870)
Net loss per common share, basic and diluted (in dollars per share)	($0.02)	($0.01)	($0.05)	($0.04)
Weighted average number of common shares outstanding, basic and diluted (in shares)	17,523,044	13,416,949	17,092,088	13,005,773

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	($1,786,541)	$0	$16,747	$11,560,249	($13,363,537)
Balance (in shares) at Dec. 31, 2013	'	0	16,747,247	'	'
Common stock issued for services rendered	360,341	0	375	359,966	0
Common stock issued for services rendered (in shares)	'	0	375,000	'	'
Common stock issued in settlement of convertible notes payable, line of credit and accrued interest	486,557	0	537	486,020	0
Common stock issued in settlement of convertible notes payable, line of credit and accrued interest (in shares)	'	0	536,557	'	'
Common stock issued in connection with loan acquisition	0	0	30	-30	0
Common stock issued in connection with loan acquisition (in shares)	'	0	30,000	'	'
Net loss	-859,290	0	0	0	-859,290
Balance at Sep. 30, 2014	($1,798,933)	$0	$17,689	$12,406,205	($14,222,827)
Balance (in shares) at Sep. 30, 2014	'	0	17,688,804	'	'

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net Loss	($859,290)	($558,870)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation and amortization	411,575	373,803
Amortization of financing costs	62,058	51,477
Amortization of debt discount in connection with convertible note	0	280,125
Bad debt expense	365,712	0
Stock based compensation	137,001	155,875
Change in fair value of debt derivative	0	-187,351
Changes in operating assets and liabilities:	'	'
Accounts receivable	-1,208,082	-646,621
Prepaid expenses and other	-38,110	-83,256
Restricted funds	-84,426	-37,163
Accounts payable and accrued expenses	757,131	306,412
Unearned income	-32,835	1,322
Net cash (used in) operating activities	-489,267	-344,247
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of equipment	-145,645	-319,762
Net increase in long term deposits	0	12,757
Net cash used in investing activities	-145,645	-307,005
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Net (payments) proceeds from related party line of credit	0	-11,882
Proceeds from advances	50,000	0
Proceeds from convertible note payable	0	257,000
Proceeds from lines of credit	552,000	1,086,404
Proceeds from notes payable	0	152,659
Net payments on notes payable	-569,228	-702,954
Net cash provided by financing activities	32,772	781,227
Net (decrease) increase in cash and cash equivalents	-602,140	129,975
Cash and cash equivalents, beginning of period	739,158	67,045
Cash and cash equivalents, end of period	137,018	197,020
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	'	'
Cash paid during the period for interest	651,228	703,841
Cash paid during the period for taxes	0	0
Supplemental Disclosure on non-cash investing and financing activities:	'	'
Common stock issued in settlement of accrued expenses	166,340	0
Common stock issued in connection with acquisition of patent	0	286,500
Common stock issued to acquire 10% interest in MedTech Diagnostics, LLC	0	450,000
Line of Credit [Member]	'	'
Supplemental Disclosure on non-cash investing and financing activities:	'	'
Debt Conversion, Original Debt, Amount	150,000	0
Convertible Notes Payable [Member]	'	'
Supplemental Disclosure on non-cash investing and financing activities:	'	'
Debt Conversion, Original Debt, Amount	336,557	0
Future Services [Member]	'	'
Supplemental Disclosure on non-cash investing and financing activities:	'	'
Debt Conversion, Original Debt, Amount	$98,000	$0

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (MedTech Diagnostics, LLC [Member])	Sep. 30, 2014
MedTech Diagnostics, LLC [Member]	'
Noncontrolling Interest, Ownership Percentage by Parent	10.00%

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 — SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION

	A summary of the significant accounting policies applied in the presentation of the accompanying unaudited condensed consolidated financial statements follows:

	General

	The (a) condensed consolidated balance sheet as of December 31, 2013, which has been derived from the audited financial statements of First Choice Healthcare Solutions, Inc. (“FCHS” and including, where appropriate, its consolidated subsidiaries, the “Company”), and (b) the unaudited condensed consolidated interim financial statements as of September 30, 2014 of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2014.

	Basis of Presentation

	Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

	As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.

	On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement.

	The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc. and First Choice - Brevard. All significant intercompany balances and transactions have been eliminated in consolidation.

	Use of Estimates

	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

	Revenue Recognition

	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “Revenue Recognition” (“ASC 605-10”) which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

	ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “Multiple-Element Arrangements” (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company's financial position and results of operations was not significant.

	The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “Health Care Entities” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our Payers.

	Patient Service Revenue

	The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.

	Rental Revenue

	FCID Holdings, Inc. has one real estate holding, Marina Towers, LLC, a 78,000 square foot, Class A, six-story building located on the Indian River in Melbourne, Florida. In addition to housing our corporate headquarters and First Choice-Brevard, the building, which averages 95% annual occupancy, also leases approximately 55,000 square feet of commercial office space to third party tenants. The Company recognizes rental revenue associated with the period of time facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).

	Cash and Cash Equivalents

	The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of September 30, 2014, the Company had $137,018 in cash.

	Concentrations of Credit Risk

	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

	Accounts Receivable

	Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.

		·	Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.

		·	Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

	As of September 30, 2014 and December 31, 2013, the Company’s provision for bad debts was $726,996 and $361,284, respectively.

	Patents

	Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company’s common stock to a related party. The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The patent costs are amortized over its expected useful life of 15 years. The amortization for the three and nine months ended September 30, 2014 was $14,325. Accumulated amortization of patent costs was $14,325 and $-0- at September 30, 2014 and December 31, 2013, respectively.

	Property and Equipment

	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 39 years.

Capitalized Financing Costs

Capitalized financing costs represent costs incurred in connection with obtaining the debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and nine months ended September 30, 2014 was $20,685 and $62,057, respectively; and for the three and nine months ended September 30, 2013 was $22,802 and $51,477, respectively. Accumulated amortization of deferred financing costs was $210,684 and $133,812 at September 30, 2014 and December 31, 2013, respectively.

Segment Information

Accounting Standards Codification subtopic “Segment Reporting” 280-10 (“ASC 280-10”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s two principal operating segments (see Note 10 – Segment Information).

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, “Income Taxes” (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.

Net Loss Per Share

The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, “Earnings Per Share” (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS.

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of potentially issuable shares of common stock such as those related to the Company’s issued convertible debt, warrants and stock options (calculated using the treasury stock method). Fully diluted shares outstanding were 23,594,546 and 15,628,755 for the three months ended September 30, 2014 and 2013, respectively and 20,843,589 and 15,217,578 for the nine months ended September 30, 2014 and 2013, respectively.

Stock-Based Compensation

Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of September 30, 2014, the Company had no non-employee options outstanding to purchase shares of common stock.

Fair Value

Accounting Standards Codification subtopic 825-10, “Financial Instruments” (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

Recent Accounting Pronouncements

The FASB has issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

LIQUIDITY

LIQUIDITY	9 Months Ended
LIQUIDITY	Sep. 30, 2014
Liquidity Disclosures [Abstract]	'
Liquidity Disclosure [Text Block]	'
	NOTE 2 – LIQUIDITY

	The Company incurred various non-recurring expenses in 2013 in connection with development of its medical practice. Management believes the positive year-end earnings before interest, taxes, depreciation and amortization and the continuing trend of positive growth before interest, taxes, depreciation and amortization through September 30, 2014 will support improved liquidity. In the fourth quarter of 2013, the Company paid off or converted to equity a total of $1,238,480 in outstanding debt. Currently, the Company has two main sources of liquidity, its line of credit with CT Capital, LP and revenue received from its real estate interest, FCID Holdings, Inc.

	On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership for an accounts receivable line of credit in the maximum aggregate amount of $1,500,000. Under the line of credit with CT Capital, the Company reduced the annual interest rate from 12% per annum to 6% per annum in exchange for the issuance to CT Capital of 100,000 restricted shares of the Company’s common stock. As of September 30, 2014, the Company has used $1,202,000 of the amount available under the line of credit.

	The Company’s wholly owned subsidiary, FCID Holdings, Inc. (“FCID Holdings”) operates its real estate interests. Currently, FCID Holdings has one real estate holding, Marina Towers, LLC, a 78,000 square foot, Class A, six-story building located on the Indian River in Melbourne, Florida. In addition to housing the Company’s corporate headquarters and First Choice – Brevard, the building, which averages 95% annual occupancy, also leases approximately 55,000 square feet of commercial office space to tenants.

	The Company believes that ongoing operations of Marina Towers, LLC and the current strong, positive cash balance along with continued execution of its business development plan will allow the Company to further improve its working capital and currently anticipates that it will have sufficient capital resources to meet projected cash flow requirements through April 2015. However, in order to execute the Company’s business development plan, which there can be no assurance it will do, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may be required to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash.

CASH_RESTRICTED

CASH - RESTRICTED	9 Months Ended
CASH - RESTRICTED	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Restricted Cash and Cash Equivalents Disclosure [Text Block]	'
	NOTE 3 — CASH - RESTRICTED

	Cash-restricted is comprised of funds deposited to and held by the mortgage lender for payments of property taxes, insurance, replacements and major repairs of the Company's commercial building. The majority of the restricted funds are reserved for tenant improvements. As of September 30, 2014 the Company had $340,672 in restricted cash as compared to $256,246 at December 31, 2013.

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	9 Months Ended
PROPERTY, PLANT, AND EQUIPMENT	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 4 — PROPERTY, PLANT, AND EQUIPMENT

	Property, plant and equipment at September 30, 2014 and December 31, 2013 are as follows:

		September 30,		December 31,
		2014		2013
	Land	$	1,000,000	$	1,000,000
	Building		3,055,168		3,055,168
	Building improvements		3,970,602		3,953,846
	Automobiles		29,849		29,849
	Computer equipment		327,847		210,698
	Medical equipment		2,253,639		2,238,639
	Office equipment		129,724		132,984
			10,766,829		10,621,184
	Less: accumulated depreciation		-2,341,377		-1,959,127
		$	8,425,452	$	8,662,057

	During the three and nine months ended September 30, 2014, depreciation expense charged to operations was $120,759 and $382,250, respectively and during the three and nine months ended September 30, 2013, depreciation expense charged to operations was $130,885 and $373,803, respectively.

LINE_OF_CREDIT

LINE OF CREDIT	9 Months Ended
LINE OF CREDIT	Sep. 30, 2014
Line Of Credit Facility [Abstract]	'
Line Of Credit Facilities [Text Block]	'
	NOTE 5 — LINE OF CREDIT

	Line of Credit, CT Capital

	On June 13, 2013, the Company’s subsidiary, First Choice – Brevard entered into a loan and security agreement (the “Loan Agreement”) with CT Capital, Ltd., d/b/a CT Capital, LP, a Florida limited liability partnership (the “Lender”). Under the Loan Agreement, the Lender committed to make an accounts receivable line of credit in the maximum aggregate amount of $1,500,000 to First Choice - Brevard with an interest rate of 12% per annum (the “Loan”). The maturity date of the Loan is December 31, 2016. Interest is due and payable monthly. Upon default, the interest may be adjusted to the highest rate permissible by law.

	The Loan is secured by the accounts receivable and assets of the Company’s subsidiary, First Choice – Brevard, which constitute the collateral for the repayment of the Loan. The Loan Agreement also includes covenants, representations, warranties, indemnities and events of default that are customary for facilities of this type. The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection. At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share. The Company did not record an embedded beneficial conversion feature in the note since the fair value of the common stock did not exceed the conversion rate at the date of commitment.

	On November 8, 2013, in consideration for the issuance of 100,000 restricted shares of the Company’s common stock, the Lender agreed to modify its Loan. Under the Loan Agreement, as amended, the annual rate of interest of the Loan was reduced from 12% per annum to 6% per annum and will remain at 6% until November 1, 2015. All other terms under the Loan Agreement remain the same.

	The obligations of the Company under the Loan Agreement, as amended, are guaranteed by certain affiliates of the Company, including a personal guarantee issued by the Company’s Chief Executive Officer.

	During the nine months ended September 30, 2014, the Company issued 200,000 shares of its common stock upon the election by Lender to convert $150,000 of outstanding principal amount under the line of credit.

CONVERTIBLE_NOTE_PAYABLE

CONVERTIBLE NOTE PAYABLE	9 Months Ended
CONVERTIBLE NOTE PAYABLE	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 6 — CONVERTIBLE NOTE PAYABLE

	On November 8, 2013, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Hillair Capital Investments L.P. ("Hillair") in exchange for the issuance of (i) a $2,320,000, 8% original issue discount convertible debenture, which was originally due on December 28, 2013 and subsequently extended on December 28, 2013 through November 1, 2015 (the “Debenture”), and (ii) a common stock purchase warrant (the “Warrant”) to purchase up to 2,320,000 shares of the Company’s common stock at an exercise price of $1.35 per share, which may be exercised on a cashless basis, until November 8, 2018. The Debenture and the Warrant may not be converted if such conversion would result in Hillair beneficially owning in excess of 4.99% of the Company’s common stock. Hillair may waive this 4.99% restriction with 61 days’ notice to the Company.

	The Company issued to Hillair the Debenture with the Warrant for the net purchase price of $2,000,000 (reflecting the $320,000 original issue discount of the Debenture). Until the Debenture is no longer outstanding, the Debenture is convertible, in whole or in part at the option of Hillair, into shares of common stock, subject to certain conversion limitations set forth above. The Company, however, has reserved the right to pay the Debenture in cash. The conversion price for the Debenture is $1.00 per share, subject to adjustment for stock splits, stock dividends, and sales of securities for less than $1.00 per share or other distributions by the Company. As a result of the Company achieving certain milestones set forth in the Securities Purchase Agreement, however, the conversion price of the Debenture will not be reduced to less than $1.00 per share as a result of any subsequent sales of securities for less than $1.00 per share of common stock.

	The Company will be obligated to redeem $580,000 of principal on February 1, 2015, May 1, 2015, August 1, 2015 and November 1, 2015, plus accrued but unpaid interest and any other amounts that may be owed to the holder of the Debenture on those dates. Interest on the Debenture accrues at the rate of 8% annually and is payable quarterly on August 1, November 1, February 1, and May 1, beginning on August 1, 2014. Interest is payable in cash or at the Company’s option in shares of the Company’s common stock, provided certain conditions are met. The August 1^st and November 1^st 2014 payments have been made.

	On or after May 8, 2014, subject to certain conditions set forth in the Debenture, the Company may elect to prepay any portion of the principal amount of the Debenture, subject to providing advance notice to the holder of the Debenture, at 120% of the then outstanding principal amount of the Debenture, plus accrued but unpaid interest and any other amounts then owed to the holder of the Debenture as further set forth therein. On May 8, 2014, Hillair elected to convert the aggregate amount of $104,000 of its Debenture, representing $100,000 of principal and $4,000 of interest, into 104,000 shares of the Company’s common stock.

	To secure the Company’s obligations under the Debenture, the Company granted Hillair a security interest in certain of its and its subsidiaries’ assets in the Company as described in the Securities Purchase Agreement. In addition, certain of the Company’s subsidiaries agreed to guarantee the Company’s obligations pursuant to the guaranty agreements.

	In connection with the issuance of the Debenture, the Company issued the Warrant, granting the holder the right to acquire an aggregate of 2,320,000 shares of the Company’s common stock at $1.35 per share. In accordance with ASC 470-20, the Company recognized the value attributable to the Warrant and the conversion feature of the Debenture in the amount of $1,871,117 to additional paid-in capital and a discount against the notes. The Company valued the warrants in accordance with ASC 470-20 using the Black-Scholes pricing model and the following assumptions: contractual terms of 3.6 years, an average risk free interest rate of 1.42%, a dividend yield of 0%, and volatility of 147.94%.

	On April 30, 2014, Hillair agreed to waive its right to participate in the Company’s future financings for a certain time period and under certain circumstances, as disclosed in the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission on May 1, 2014.

	On June 30, 2014, Hillair elected to convert the aggregate amount of $104,700 of its Debenture, representing $100,000 of principal and $4,700 of interest, into 104,700 shares of the Company’s common stock.

	On August 4, 2014, Hillair elected to convert accrued interest of $127,857 into 127,857 shares of the Company’s common stock.

NOTES_PAYABLE

NOTES PAYABLE	9 Months Ended
NOTES PAYABLE	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-term Debt [Text Block]	'
	NOTE 7 — NOTES PAYABLE

	Notes payable as of September 30, 2014 and December 31, 2013 are comprised of the following:

		September 30,		December 31,
		2014		2013
	Mortgage payable	$	7,281,526	$	7,353,398
	Note payable, GE Capital (construction), MRI		165,121		278,287
	Note payable, GE Capital (construction), 2		59,336		100,977
	Note Payable, GE Capital (MRI)		1,307,717		1,592,278
	Note Payable, GE Capital (X-ray)		153,076		184,001
	Note Payable, GE Arm		97,756		114,597
	Note payable, Auto		17,864		22,211
	Capital lease, Equipment		27,636		33,511
			9,110,032		9,679,260
	Less: current portion		-781,162		-743,787
		$	8,328,870	$	8,935,473

	Mortgage Payable

	On August 12, 2011, the Company refinanced its existing mortgage note payable as described below providing additional working capital funds. The aggregate amount of the note of $7,550,000 bears 6.10% interest per annum with monthly payments of $45,752.61 beginning in October 2011 based on a 30 year amortization schedule with all remaining principal and interest due in full on September 16, 2016. The note is secured by land and the building along with first priority assignment of leases and rents. Tenant rents are mailed to a lockbox operated by the mortgage service company. In addition, the Company's Chief Executive Officer provided a limited personal guaranty.

	In connection with the refinancing of the mortgage note payable, the Company incurred financing costs of $286,723. The capitalized financing costs are amortized ratably over the term of the mortgage note payable.

	Note Payable – Equipment Financing

	On May 21, 2012, the Company entered into a note payable with GE Healthcare Financial Services (“GE Capital”) in the amount of approximately $2.4 million for equipment financing.

	The Company also currently has two construction loans outstanding. As of December 2012, the construction loans are payable in 35 monthly payments (first three payments are $nil) including interest at 7.38%. On May 29, 2012, the Company drew down a total of $450,000 against the first construction loan. On September 24, 2012, the Company drew down a total of $150,000 against the second construction loan.

	The Company entered into equipment finance leases for a total aggregate amount of $2,288,679, subject to delivery and acceptance of the underlying equipment. All notes and finance leases have been personally guaranteed by the Company's Chief Executive Officer.

	On August 22, 2012, the Company accepted the delivery of X-ray equipment under the equipment finance lease. As such, the component piece accepted of $212,389 is due over 60 months and the associated monthly payment is $0 for the first three months and $4,300 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $1,384 for the first three months and $4,575 per month for the remaining monthly payments.

	On September 27, 2012, the Company accepted the delivery of MRI equipment under the equipment finance lease. As such, the component piece accepted of $1,771,390 is due over 60 months and the associated monthly payment is $0 for the first three months and $38,152 per month for the remaining 57 months including interest at 7.9375% per annum. On March 8, 2013, the Company amended the equipment finance lease to interest only payments of $11,779 for the first three months and $38,152 per month for the remaining monthly payments.

	On February 25, 2013, the Company accepted the delivery of C-arm equipment under the equipment finance lease. As such, the component piece accepted of $117,322 is due over 63 months and the associated monthly payment is $0 for the first three months and $2,388 for the remaining 60 months, including interest at 7.39% per annum.

	Note Payable – Auto

	On May 21, 2012, the Company issued a note payable, in the amount of $29,850, due in monthly installments of $593 including interest of 6.99%. The note is set to mature in June 2017, and is secured by related equipment. The outstanding balance on the note payable as of September 30, 2014 was $17,864.

	Capital Lease – Equipment

	On June 11, 2013, the Company entered into a lease agreement to acquire equipment with 48 monthly payments of $956.45 payable through June 1, 2017 with an effective interest rate of 14.002% per annum. The Company may elect to acquire the leased equipment at a nominal amount at the end of the lease.

	Aggregate maturities of long-term debt as of September 30:

		Amount
	Three months ended December 31, 2014	$	174,559
	Year ended December 31, 2015		715,085
	Year ended December 31, 2016		7,632,286
	Year ended December 31, 2017		523,608
	Year ended December 31, 2018 and thereafter		64,494
	Total	$	9,110,032

CAPITAL_STOCK

CAPITAL STOCK	9 Months Ended
CAPITAL STOCK	Sep. 30, 2014
Capital Stock [Abstract]	'
Capital Stock [Text Block]	'
	NOTE 8 — CAPITAL STOCK

	During the nine months ended September 30, 2014, the Company issued an aggregate of 200,000 shares of its common stock in conversion of principal due on the line of credit.

	During the nine months ended September 30, 2014, the Company issued 336,557 shares of its common stock in the conversion of convertible notes payable, and accrued interest.

	During the nine months ended September 30, 2014, the Company issued an aggregate of 175,000 shares of its common stock for various consulting services rendered.

	During the nine months ended September 30, 2014, the Company issued 100,000 shares of common stock for future services of $98,000. The Company recorded the fair value as prepaid expenses and amortizes the fair value of the shares issued as stock based compensation during the requisite service period to operations. During the three and nine months ended September 30, 2014, the Company recorded $12,250, respectively, as stock based compensation.

	During the nine months ended September 30, 2014, the Company issued an aggregate of 130,000 shares of its common stock in employee incentives.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
STOCK OPTIONS AND WARRANTS	Sep. 30, 2014
Stock Options and Warrants Disclosure [Abstract]	'
Stock Options and Warrants Disclosure [Text Block]	'
	NOTE 9 — STOCK OPTIONS AND WARRANTS

	Warrants

	The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of September 30, 2014:

					Warrants Outstanding					Warrants Exercisable
								Weighted				Weighted
	Price		Outstanding				Expiration Date	Price		Exercisable		Price
	$	1.35			2,320,000		8-Nov-18	$	1.35		2,320,000	$	1.35
		3.6			1,875,000		31-Dec-16		3.6		1,875,000		3.6
					4,195,000			$	2.36		4,195,000	$	2.36

	Transactions involving stock warrants issued to non-employees are summarized as follows:

						Weighted
						Average
		Number of				Price
		Shares				Per Share
	Outstanding at December 31, 2012:			1,875,000		$	3.6
	Granted			2,320,000			1.35
	Exercised			-			-
	Expired			-			-
	Outstanding at December 31, 2013:			4,195,000			2.36
	Granted			-			-
	Exercised			-			-
	Expired			-			-
	Outstanding at September 30, 2014:			4,195,000		$	2.36

	As of September 30, 2014, the Company had no outstanding options.

SEGMENT_REPORTING

SEGMENT REPORTING	9 Months Ended
SEGMENT REPORTING	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	NOTE 10 — SEGMENT REPORTING

	The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has two reportable segments: real estate and healthcare services.

	The real estate segment derives revenue from the operating leases of its owned building, whereas the healthcare services segment derives revenue for medical services provided to patients.

	Information concerning the operations of the Company's reportable segments is as follows:

	Summary Statement of Operations for the three months ended September 30, 2014:

			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,627,157		$	-		$	-		$	1,627,157
	Rental revenue			373,200			-			-			-109,312			263,888
	Total Revenue			373,200			1,627,157			-			-109,312			1,891,045

	Operating expenses:
	Salaries & benefits			3,000			834,406			88,107			-			925,513
	Other operating expenses			112,407			404,604			-			-109,312			407,699
	General and administrative			22,067			283,949			242,619			-			548,635
	Depreciation and amortization			69,219			66,540			14,325			-			150,084
	Total operating expenses			206,693			1,589,499			345,051			-109,312			2,031,931

	Net income (loss) from operations:			166,507			37,658			-345,051			-			-140,886

	Interest expense			-113,689			-56,162			-44,947			-			-214,798
	Amortization of financing costs			-14,337			-6,349			-			-			-20,686
	Other income (expense)			750			-			-			-			750

	Net Income (loss):			39,231			-24,853			-389,998			-			-375,620

	Income taxes			-			-			-			-			-

	Net income (loss)		$	39,231		$	-24,853		$	-389,998		$	-		$	-375,620

	Summary Statement of Operations for the three months ended September 30, 2013:

			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,395,610		$	-		$	-		$	1,395,610
	Rental revenue			365,839			-			-			-106,719			259,120
	Total Revenue			365,839			1,395,610			-			-106,719			1,654,730

	Operating expenses:
	Salaries & benefits			3,000			574,487			158,401			-			735,888
	Other operating expenses			95,689			357,696			-			-100,351			353,034
	General and administrative			21,791			140,039			136,736			-			298,566
	Depreciation and amortization			41,571			82,807			-			-			124,378
	Total operating expenses			162,051			1,155,029			295,137			-100,351			1,511,866

	Net income (loss) from operations:			203,788			240,581			-295,137			-6,368			142,864

	Interest expense			-115,241			-78,039			-109,310			-			-302,590
	Amortization of financing costs			-14,337			-8,465			-			-			-22,802
	Gain on change in derivative liability			-			-			-1,631			-			-1,631
	Other income (expense)			750			-			-			-			750

	Net Income (loss):			74,960			154,077			-406,078			-6,368			-183,409

	Income taxes			-			-			-			-			-

Net income (loss)		$	74,960		$	154,077		$	-406,078		$	-6,368		$	-183,409


Summary Statement of Operations for the nine months ended September 30, 2014:

		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue		$	-		$	5,448,428		$	-		$	-		$	5,448,428
Rental revenue			1,110,171			-			-			-325,637			784,534
Total Revenue			1,110,171			5,448,428			-			-325,637			6,232,962

Operating expenses:
Salaries & benefits			9,000			2,810,844			261,996			-			3,081,840
Other operating expenses			326,008			1,263,675			-			-325,637			1,264,046
General and administrative			65,789			849,110			708,856			-			1,623,755
Depreciation and amortization			207,447			189,803			14,325			-			411,575
Total operating expenses			608,244			5,113,432			985,177			-325,637			6,381,216

Net income (loss) from operations:			501,927			334,996			-985,177			-			-148,254

Interest expense			-339,780			-171,450			-139,998			-			-651,228
Amortization of financing costs			-43,011			-19,047			-			-			-62,058
Other income (expense)			2,250			-			-			-			2,250

Net Income (loss):			121,386			144,499			-1,125,175			-			-859,290

Income taxes			-			-			-			-			-

Net income (loss)		$	121,386		$	144,499		$	-1,125,175		$	-		$	-859,290

Summary Statement of Operations for the nine months ended September 30, 2013:

		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue		$	-		$	3,739,435		$	-		$	-		$	3,739,435
Rental revenue			1,104,405			-			-			-317,859			786,546
Total Revenue			1,104,405			3,739,435			-			-317,859			4,525,981

Operating expenses:
Salaries & benefits			9,000			1,583,238			408,198			-			2,000,436
Other operating expenses			289,765			994,017			-			-317,859			965,923
General and administrative			61,132			447,023			390,755			-			898,910
Depreciation and amortization			123,313			250,490			-			-			373,803
Total operating expenses			483,210			3,274,768			798,953			-317,859			4,239,072

Net income (loss) from operations:			621,195			464,667			-798,953			-			286,909

Interest expense			-347,406			-208,773			-427,787			-			-983,966
Amortization of financing costs			-43,011			-8,466			-			-			-51,477
Gain on change in derivative liability			-			-			187,351			-			187,351
Other income (expense)			2,313			-			-			-			2,313

Net Income (loss):			233,091			247,428			-1,039,389			-			-558,870

Income taxes			-			-			-			-			-

Net income (loss)		$	233,091		$	247,428		$	-1,039,389		$	-		$	-558,870


Assets:

		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Assets:
At September 30, 2014:		$	6,688,386		$	4,837,380		$	408,060		$	-		$	11,933,826
At December 31, 2013:		$	6,873,839		$	4,178,091		$	761,367		$	-		$	11,813,297

Assets acquired
Three month ended September 30, 2014:		$	-		$	57,663		$	-		$	-		$	57,663
Three months ended September 30, 2013:		$	-		$	54,255		$	-		$	-		$	54,255
Nine months ended September 30, 2014:		$	16,758		$	128,887		$	-		$	-		$	145,645
Nine months ended September 30, 2013:		$	67,192		$	252,570		$	-		$	-		$	319,762

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 11 – COMMITMENTS AND CONTINGENCIES

	On December 9, 2011, FCID Medical, Inc. and First Choice Medical Group of Brevard, LLC, both wholly-owned subsidiaries of the Company (collectively, the “Company”) entered into a five (5) year Billing and Collection Agreement (the “Agreement”) with MedTRX Health Care Solutions, LLC and MedTRX Collection Services LLC (collectively, “MedTRX”). Under the terms of the Agreement, MedTRX was to provide the Company with proprietary IT billing and collection software systems. MedTRX has claimed that the Company breached the Agreement, and that the Agreement has been terminated. MedTRX, on July 25, 2014, filed a demand for arbitration with the American Arbitration Association to be conducted in New York, New York. The Company believes the claims of MedTRX are without merit and intends to file a counterclaim of its own for multiple breaches of the Agreement by MedTRX. Colin Halpern, a member of our Board of Directors, Is the Managing Member of MedTRX Provider Network, LLC, which is an affiliate of MedTRX. However, no assurance can be given that any amounts ultimately due by the Company, will not have a material impact on the Company’s financial condition.

	On April 10, 2014, the Company terminated the employment of Dr. David E. Dominguez in accordance with the terms of his five (5) year Employment Agreement dated September 26, 2013 (the “Employment Agreement”). Dr. Dominguez, on June 5, 2014, commenced an action against the Company in the Circuit Court of the Eighteenth Judicial Circuit In and For Brevard County, Florida, alleging that his termination was in breach of the Employment Agreement. The action was settled by Agreement dated September 4, 2014, with no settlement cost to the Company, without either party admitting any liability, and the filing of Joint Stipulation of Dismissal.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 12 - SUBSEQUENT EVENTS

	Effective as of November 3, 2014, the Board of Directors of First Choice Healthcare Solutions, Inc. (the “Company”) appointed Gary D. Pickett as Chief Financial Officer, Secretary and Treasurer of the Company. Mr. Pickett succeeds Donald A. Bittar as Chief Financial Officer, Secretary and Treasurer of the Company. Mr. Bittar announced he would be retiring effective November 3, 2014. Mr. Bittar will continue to serve as a member of the Company’s Board of Directors.

	Gary D. Pickett, age 63, a certified public accountant, holds an MBA from the University of Tampa, a BS degree in Accounting from Florida State University, and has served four years as a field artillery officer in the United States Army. From March 2006 to May 2014, Mr. Pickett served as a senior financial executive with Bovie Medical Corporation (NYSE: BVX), a microcap publicly-traded medical manufacturing company, including as their Chief Financial Officer, Secretary and Treasurer. Prior to joining Bovie, Mr. Pickett held positions with Progress Energy Services of Raleigh, NC, (Director of Financial Systems), and with Progress Rail Services, a subsidiary of Progress Energy Services in Albertville, AL (Vice-President and Controller). Mr. Pickett has extensive experience in Sarbanes-Oxley implementation as well as GAAP accounting and SEC Reporting.

	In connection with his appointment as Chief Financial Officer, the Company awarded Mr. Pickett 50,000 shares of Common Stock which vest in two (2) equal annual installments on the first and second anniversaries of his employment. Mr. Pickett is also entitled to receive up to $6,000 in relocation expenses.

	For estate planning purposes, Mr. Romandetti, the Company’s Chief Executive Officer and President, has gifted the 1,800,000 shares of the Company’s common stock owned by Marina Towers Holdings, LLC (“Holdings”), a Florida limited liability company. The recipients of the gifts were his local church organization (100,000 shares) and the remaining 1,700,000 shares will be distributed among his children’s trust accounts. Mr. Romandetti is the managing member of Holdings. In addition, Mr. Romandetti, as the managing member of GIRTFT, LLC (“GIRTFT”), a Florida limited liability company, has instructed that the 5,750,000 shares owned by GIRTFT be transferred to a family trust.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation

	Effective April 4, 2012, Medical Billing Assistance, Inc., a Colorado corporation (“Medical Billing”), merged with and into the Company. The effect of the merger was that Medical Billing reincorporated from Colorado to Delaware (the “Reincorporation”). The Company is deemed to be the successor issuer of Medical Billing under Rule 12g-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

	As a result of the Reincorporation, the Company changed its name to First Choice Healthcare Solutions, Inc. and its shares underwent an effective four-for-one reverse split. Other than the foregoing, the Reincorporation did not result in any change in the business, management, fiscal year, accounting, and location of the principal executive offices, assets or liabilities of the Company.

	On April 2, 2012, the Company completed its acquisition of First Choice Medical Group of Brevard, LLC (“First Choice – Brevard”), pursuant to the Membership Interest Purchase Closing Agreement (the “Purchase Agreement”). The Company has been managing the practice of First Choice – Brevard since November 1, 2011, pursuant to a Management Services Agreement.

	The unaudited condensed consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries FCID Holdings, Inc., MTMC of Melbourne, Inc., Marina Towers, LLC, FCID Medical Inc. and First Choice - Brevard. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates

	The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition

	The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, “Revenue Recognition” (“ASC 605-10”) which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.

	ASC 605-10 incorporates Accounting Standards Codification subtopic 605-25, “Multiple-Element Arrangements” (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on the Company's financial position and results of operations was not significant.

	The Company recognizes in accordance with Accounting Standards Codification subtopic 954-310, “Health Care Entities” (“ASC 954-310”), significant patient service revenue at the time the services are rendered, even though it does not assess the patient’s ability to pay. Therefore, The Company’s interim and annual periods reports disclose both, its policy for assessing and disclosing the timing and amount of uncollectable patient service revenue recognized as doubtful. Qualitative and quantitative information about significant changes in the allowance for doubtful accounts related to patient accounts receivable are disclosed in the Company’s reports. These estimates are based upon the past history and identified trends for each of our Payers.

	Patient Service Revenue

	The Company recognizes patient service revenue associated with services provided to patients who have third-party payer coverage on the basis of contractual rates for the services provided. For uninsured or self-pay patients that do not qualify for charity care, the Company recognizes revenue on the basis of its standard rates for services provided (or on the basis of discounted rates, if negotiated or provided by policy). On the basis of historical experience, a portion of the Company’s patient service revenue may be potentially uncollectible due to patients who are unable or unwilling to pay for the services provided or the portion of their bill for which they are responsible. Thus, the Company records a provision for bad debts related to potentially uncollectible patient service revenue in the period the services are provided.

	Rental Revenue

	FCID Holdings, Inc. has one real estate holding, Marina Towers, LLC, a 78,000 square foot, Class A, six-story building located on the Indian River in Melbourne, Florida. In addition to housing our corporate headquarters and First Choice-Brevard, the building, which averages 95% annual occupancy, also leases approximately 55,000 square feet of commercial office space to third party tenants. The Company recognizes rental revenue associated with the period of time facility is leased at the contractual lease rates (or on the basis of discounted rates, if negotiated).


Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents

	The Company considers cash and cash equivalents to consist of cash on hand and investments having an original maturity of 90 days or less that are readily convertible into cash. As of September 30, 2014, the Company had $137,018 in cash.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Credit Risk

	The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable

	Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its past history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts.

		·	Rental receivables. Accounts receivables from rental activities are periodically evaluated for collectability in determining the appropriate allowance for doubtful account provision for bad debts and provision of bad debts.

		·	Patient receivables. Accounts receivables from services provided to patients who have third-party coverage, the Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.

	As of September 30, 2014 and December 31, 2013, the Company’s provision for bad debts was $726,996 and $361,284, respectively.

Patents [Policy Text Block]	'
	Patents

	Intangible assets with finite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are not amortized, but are tested for impairment annually. The Company’s intangible assets with finite lives are patent costs, which are amortized over their economic or legal life, whichever is shorter. These patent costs were acquired on September 7, 2013 by the issuance of 636,666 shares of the Company’s common stock to a related party. The shares of common stock were valued at $286,500, which was estimated to be approximately the fair value of the patent acquired and did not materially differ from the fair value of the common stock. The patent costs are amortized over its expected useful life of 15 years. The amortization for the three and nine months ended September 30, 2014 was $14,325. Accumulated amortization of patent costs was $14,325 and $-0- at September 30, 2014 and December 31, 2013, respectively.

Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment

	Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 39 years.

Capitalized Financing Cost [Policy Text Block]	'
	Capitalized Financing Costs

	Capitalized financing costs represent costs incurred in connection with obtaining the debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt. The amortization for the three and nine months ended September 30, 2014 was $20,685 and $62,057, respectively; and for the three and nine months ended September 30, 2013 was $22,802 and $51,477, respectively. Accumulated amortization of deferred financing costs was $210,684 and $133,812 at September 30, 2014 and December 31, 2013, respectively.

Segment Reporting, Policy [Policy Text Block]	'
	Segment Information

	Accounting Standards Codification subtopic “Segment Reporting” 280-10 (“ASC 280-10”) establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. ASC 280-10 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s two principal operating segments (see Note 10 – Segment Information).

Income Tax, Policy [Policy Text Block]	'
	Income Taxes

	The Company follows Accounting Standards Codification subtopic 740-10, “Income Taxes” (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.

Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share

	The Company accounts for net loss per share in accordance with Accounting Standards Codification subtopic 260-10, “Earnings Per Share” (“ASC 260-10”), which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the statement of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS.

	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. It excludes the dilutive effects of potentially issuable shares of common stock such as those related to the Company’s issued convertible debt, warrants and stock options (calculated using the treasury stock method). Fully diluted shares outstanding were 23,594,546 and 15,628,755 for the three months ended September 30, 2014 and 2013, respectively and 20,843,589 and 15,217,578 for the nine months ended September 30, 2014 and 2013, respectively.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation

	Share-based compensation issued to employees is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. The Company measures the fair value of the share-based compensation issued to non-employees using the stock price observed in the arms-length private placement transaction nearest the measurement date (for stock transactions) or the fair value of the award (for non-stock transactions), which were considered to be more reliably determinable measures of fair value than the value of the services being rendered. The measurement date is the earlier of (1) the date at which commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. As of September 30, 2014, the Company had no non-employee options outstanding to purchase shares of common stock.

Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value

	Accounting Standards Codification subtopic 825-10, “Financial Instruments” (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

	The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Neither of these statements had an impact on the Company’s financial position, results of operations nor cash flows.

New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements

	The FASB has issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This ASU requires that a performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

	The FASB has issued ASU No. 2014-09, Revenue from Contracts with Customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective on January 1, 2017 and should be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the ASU recognized at the date of initial application. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s condensed consolidated financial position and results of operations.

	There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT, AND EQUIPMENT (Tables)	9 Months Ended
PROPERTY, PLANT, AND EQUIPMENT (Tables)	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment at September 30, 2014 and December 31, 2013 are as follows:

		September 30,		December 31,
		2014		2013
	Land	$	1,000,000	$	1,000,000
	Building		3,055,168		3,055,168
	Building improvements		3,970,602		3,953,846
	Automobiles		29,849		29,849
	Computer equipment		327,847		210,698
	Medical equipment		2,253,639		2,238,639
	Office equipment		129,724		132,984
			10,766,829		10,621,184
	Less: accumulated depreciation		-2,341,377		-1,959,127
		$	8,425,452	$	8,662,057

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	9 Months Ended
NOTES PAYABLE (Tables)	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Notes payable as of September 30, 2014 and December 31, 2013 are comprised of the following:

		September 30,		December 31,
		2014		2013
	Mortgage payable	$	7,281,526	$	7,353,398
	Note payable, GE Capital (construction), MRI		165,121		278,287
	Note payable, GE Capital (construction), 2		59,336		100,977
	Note Payable, GE Capital (MRI)		1,307,717		1,592,278
	Note Payable, GE Capital (X-ray)		153,076		184,001
	Note Payable, GE Arm		97,756		114,597
	Note payable, Auto		17,864		22,211
	Capital lease, Equipment		27,636		33,511
			9,110,032		9,679,260
	Less: current portion		-781,162		-743,787
		$	8,328,870	$	8,935,473

Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Aggregate maturities of long-term debt as of September 30:

		Amount
	Three months ended December 31, 2014	$	174,559
	Year ended December 31, 2015		715,085
	Year ended December 31, 2016		7,632,286
	Year ended December 31, 2017		523,608
	Year ended December 31, 2018 and thereafter		64,494
	Total	$	9,110,032

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
STOCK OPTIONS AND WARRANTS (Tables)	Sep. 30, 2014
Stock Options and Warrants Disclosure [Abstract]	'
Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]	'
	The following table summarizes the warrants outstanding and the related exercise prices for the underlying shares of the Company's common stock as of September 30, 2014:

					Warrants Outstanding					Warrants Exercisable
								Weighted				Weighted
	Price		Outstanding				Expiration Date	Price		Exercisable		Price
	$	1.35			2,320,000		8-Nov-18	$	1.35		2,320,000	$	1.35
		3.6			1,875,000		31-Dec-16		3.6		1,875,000		3.6
					4,195,000			$	2.36		4,195,000	$	2.36

Schedule Of Warrants Outstanding and Related Prices [Table Text Block]	'
	Transactions involving stock warrants issued to non-employees are summarized as follows:

						Weighted
						Average
		Number of				Price
		Shares				Per Share
	Outstanding at December 31, 2012:			1,875,000		$	3.6
	Granted			2,320,000			1.35
	Exercised			-			-
	Expired			-			-
	Outstanding at December 31, 2013:			4,195,000			2.36
	Granted			-			-
	Exercised			-			-
	Expired			-			-
	Outstanding at September 30, 2014:			4,195,000		$	2.36

SEGMENT_REPORTING_Tables

SEGMENT REPORTING (Tables)	9 Months Ended
SEGMENT REPORTING (Tables)	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Summary Statement of Operations for the three months ended September 30, 2014:

			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,627,157		$	-		$	-		$	1,627,157
	Rental revenue			373,200			-			-			-109,312			263,888
	Total Revenue			373,200			1,627,157			-			-109,312			1,891,045

	Operating expenses:
	Salaries & benefits			3,000			834,406			88,107			-			925,513
	Other operating expenses			112,407			404,604			-			-109,312			407,699
	General and administrative			22,067			283,949			242,619			-			548,635
	Depreciation and amortization			69,219			66,540			14,325			-			150,084
	Total operating expenses			206,693			1,589,499			345,051			-109,312			2,031,931

	Net income (loss) from operations:			166,507			37,658			-345,051			-			-140,886

	Interest expense			-113,689			-56,162			-44,947			-			-214,798
	Amortization of financing costs			-14,337			-6,349			-			-			-20,686
	Other income (expense)			750			-			-			-			750

	Net Income (loss):			39,231			-24,853			-389,998			-			-375,620

	Income taxes			-			-			-			-			-

	Net income (loss)		$	39,231		$	-24,853		$	-389,998		$	-		$	-375,620

	Summary Statement of Operations for the three months ended September 30, 2013:

			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
	Net Patient Service Revenue		$	-		$	1,395,610		$	-		$	-		$	1,395,610
	Rental revenue			365,839			-			-			-106,719			259,120
	Total Revenue			365,839			1,395,610			-			-106,719			1,654,730

	Operating expenses:
	Salaries & benefits			3,000			574,487			158,401			-			735,888
	Other operating expenses			95,689			357,696			-			-100,351			353,034
	General and administrative			21,791			140,039			136,736			-			298,566
	Depreciation and amortization			41,571			82,807			-			-			124,378
	Total operating expenses			162,051			1,155,029			295,137			-100,351			1,511,866

	Net income (loss) from operations:			203,788			240,581			-295,137			-6,368			142,864

	Interest expense			-115,241			-78,039			-109,310			-			-302,590
	Amortization of financing costs			-14,337			-8,465			-			-			-22,802
	Gain on change in derivative liability			-			-			-1,631			-			-1,631
	Other income (expense)			750			-			-			-			750

	Net Income (loss):			74,960			154,077			-406,078			-6,368			-183,409

	Income taxes			-			-			-			-			-

	Net income (loss)		$	74,960		$	154,077		$	-406,078		$	-6,368		$	-183,409


	Summary Statement of Operations for the nine months ended September 30, 2014:

			Marina			FCID						Intercompany
			Towers			Medical			Corporate			Eliminations			Total
	Revenue:
Net Patient Service Revenue		$	-		$	5,448,428		$	-		$	-		$	5,448,428
Rental revenue			1,110,171			-			-			-325,637			784,534
Total Revenue			1,110,171			5,448,428			-			-325,637			6,232,962

Operating expenses:
Salaries & benefits			9,000			2,810,844			261,996			-			3,081,840
Other operating expenses			326,008			1,263,675			-			-325,637			1,264,046
General and administrative			65,789			849,110			708,856			-			1,623,755
Depreciation and amortization			207,447			189,803			14,325			-			411,575
Total operating expenses			608,244			5,113,432			985,177			-325,637			6,381,216

Net income (loss) from operations:			501,927			334,996			-985,177			-			-148,254

Interest expense			-339,780			-171,450			-139,998			-			-651,228
Amortization of financing costs			-43,011			-19,047			-			-			-62,058
Other income (expense)			2,250			-			-			-			2,250

Net Income (loss):			121,386			144,499			-1,125,175			-			-859,290

Income taxes			-			-			-			-			-

Net income (loss)		$	121,386		$	144,499		$	-1,125,175		$	-		$	-859,290

Summary Statement of Operations for the nine months ended September 30, 2013:

		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Revenue:
Net Patient Service Revenue		$	-		$	3,739,435		$	-		$	-		$	3,739,435
Rental revenue			1,104,405			-			-			-317,859			786,546
Total Revenue			1,104,405			3,739,435			-			-317,859			4,525,981

Operating expenses:
Salaries & benefits			9,000			1,583,238			408,198			-			2,000,436
Other operating expenses			289,765			994,017			-			-317,859			965,923
General and administrative			61,132			447,023			390,755			-			898,910
Depreciation and amortization			123,313			250,490			-			-			373,803
Total operating expenses			483,210			3,274,768			798,953			-317,859			4,239,072

Net income (loss) from operations:			621,195			464,667			-798,953			-			286,909

Interest expense			-347,406			-208,773			-427,787			-			-983,966
Amortization of financing costs			-43,011			-8,466			-			-			-51,477
Gain on change in derivative liability			-			-			187,351			-			187,351
Other income (expense)			2,313			-			-			-			2,313

Net Income (loss):			233,091			247,428			-1,039,389			-			-558,870

Income taxes			-			-			-			-			-

Net income (loss)		$	233,091		$	247,428		$	-1,039,389		$	-		$	-558,870


Assets:

		Marina			FCID						Intercompany
		Towers			Medical			Corporate			Eliminations			Total
Assets:
At September 30, 2014:		$	6,688,386		$	4,837,380		$	408,060		$	-		$	11,933,826
At December 31, 2013:		$	6,873,839		$	4,178,091		$	761,367		$	-		$	11,813,297

Assets acquired
Three month ended September 30, 2014:		$	-		$	57,663		$	-		$	-		$	57,663
Three months ended September 30, 2013:		$	-		$	54,255		$	-		$	-		$	54,255
Nine months ended September 30, 2014:		$	16,758		$	128,887		$	-		$	-		$	145,645
Nine months ended September 30, 2013:		$	67,192		$	252,570		$	-		$	-		$	319,762

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES; BASIS OF PRESENTATION (Details Textual) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Third Party Tenants [Member]

Marina Towers LLC [Member]

Common Stock [Member]

Patents [Member]

Maximum [Member]

Minimum [Member]

sqft

Summary of Significant Accounting Policies [Line Items]

Amortization Financing Costs

$20,686

$22,802

$62,058

$51,477

$14,337

$43,011

Investment Maturity Term

'90 days or less

Property, Plant and Equipment, Useful Life

'39 years

'5 years

Property, Plant and Equipment, Depreciation Methods

'straight-line method

Accumulated Amortization, Deferred Finance Costs

210,684

133,812

Allowance for Doubtful Accounts Receivable

726,996

361,284

Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount

23,594,546

15,628,755

20,843,589

15,217,578

Cash and Cash Equivalents, at Carrying Value, Total

137,018

197,020

137,018

197,020

739,158

67,045

Stock Issued During Period, Shares, Purchase of Assets

636,666

Stock Issued During Period, Value, Purchase of Assets

286,500

Area of Land, Percentage of Occupancy

95.00%

Area of Land

78,000

Land Subject to Ground Leases

55,000

Amortization of Intangible Assets

14,325

Finite-Lived Intangible Assets, Accumulated Amortization

$14,325

Finite-Lived Intangible Asset, Useful Life

'15 years

LIQUIDITY_Details_Textual

LIQUIDITY (Details Textual) (USD $)	3 Months Ended		9 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
			Marina Towers LLC [Member]	CT Capital LTD [Member]	CT Capital LTD [Member]	Third Party Tenants [Member]
			sqft			sqft
Liquidity Disclosures [Line Items]	'	'	'	'	'	'
Long-term Line of Credit	'	'	'	$1,500,000	'	'
Debt Instrument, Interest Rate During Period	'	'	'	12.00%	'	'
Debt Instrument, Interest Rate, Effective Percentage	'	'	'	6.00%	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	'	'	'	100,000	'	'
Line of Credit, Current	800,000	1,202,000	'	'	1,202,000	'
Area of Land, Percentage of Occupancy	'	'	95.00%	'	'	'
Area of Land	'	'	78,000	'	'	'
Land Subject to Ground Leases	'	'	'	'	'	55,000
Debt Conversion, Converted Instrument, Amount	$1,238,480	'	'	'	'	'

CASH_RESTRICTED_Details_Textua

CASH - RESTRICTED (Details Textual) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Restricted Cash and Cash Equivalents Items [Line Items]	'	'
Restricted Cash and Cash Equivalents	$340,672	$256,246

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT, AND EQUIPMENT (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$10,766,829	$10,621,184
Less: accumulated depreciation	-2,341,377	-1,959,127
Property, plant and equipment, net	8,425,452	8,662,057
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	1,000,000	1,000,000
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	3,055,168	3,055,168
Building Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	3,970,602	3,953,846
Automobiles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	29,849	29,849
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	327,847	210,698
Medical Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	2,253,639	2,238,639
Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$129,724	$132,984

PROPERTY_PLANT_AND_EQUIPMENT_D1

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) (USD $)	3 Months Ended		9 Months Ended
PROPERTY, PLANT, AND EQUIPMENT (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation	$120,759	$130,885	$382,250	$373,803

LINE_OF_CREDIT_Details_Textual

LINE OF CREDIT (Details Textual) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
	Line of Credit [Member]	Line of Credit [Member]	Line of Credit, CT Capital [Member]
Line of Credit Facility [Line Items]	'	'	'
Short-term Debt, Maximum Amount Outstanding During Period	'	'	$1,500,000
Line Of Credit Facility, Interest Rate During Period	'	'	12.00%
Line Of Credit Facility, Expiration Date	'	'	31-Dec-16
Line of Credit Facility, Collateral	'	'	'The advance rate is defined as: 80% of all receivables to be 120 days or less at the net collection rate of approximately 27% of total billings, excluding patient billings and collections. Additionally, allowable accounts receivable will also include 50% of all accounts receivable protected by legal letters of protection.
Debt Instrument, Convertible, Terms of Conversion Feature	'	'	'At any time, the Lender may convert all or any portion of the outstanding principal amount or interest on the Loan into common stock of the Company at a conversion price of $0.75 per share
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total	'	'	100,000
Debt Instrument, Interest Rate During Period	'	'	12.00%
Debt Instrument, Interest Rate, Effective Percentage	'	'	6.00%
Debt Conversion, Original Debt, Amount	$150,000	$0	'
Debt Conversion, Converted Instrument, Shares Issued	200,000	'	'

CONVERTIBLE_NOTE_PAYABLE_Detai

CONVERTIBLE NOTE PAYABLE (Details Textual) (USD $)	9 Months Ended		0 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Aug. 04, 2014	Sep. 30, 2014	Dec. 31, 2013	8-May-14	Jun. 30, 2014
	Sep. 30, 2014	Sep. 30, 2013	Subsequent Event [Member]	Hillair Capital Investments L P [Member]	Hillair Capital Investments L P [Member]	Convertible Debt [Member]	Convertible Debt [Member]
Debt Disclosure [Line Items]	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	'	8.00%	'	'
Debt Instrument, Face Amount	'	'	'	'	$2,320,000	$100,000	$100,000
Proceeds From Convertible Debt	0	257,000	'	'	2,000,000	'	'
Fair Value Assumptions, Expected Dividend Rate	'	'	'	0.00%	'	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	'	'	1.42%	'	'	'
Fair Value Assumptions, Expected Volatility Rate	'	'	'	147.94%	'	'	'
Fair Value Assumptions, Expected Term	'	'	'	'3 years 7 months 6 days	'	'	'
Warrants Issued, Number of Warrants	'	'	'	'	2,320,000	'	'
Warrants Issued, Exercise Price	'	'	'	'	$1.35	'	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	$1	'	'
Debt Instrument, Periodic Payment, Principal	'	'	'	'	580,000	'	'
Debt Instrument, Frequency of Periodic Payment	'	'	'	'	'quarterly	'	'
Debt Instrument, Prepayment terms, Percentage of Settlement Amount	'	'	'	120.00%	'	'	'
Debt Instrument, Unamortized Discount	'	'	'	'	320,000	'	'
Debt Instrument, Maturity Date, Description	'	'	'	'	'convertible debenture, which was originally due on December 28, 2013 and subsequently extended on December 28, 2013 through November 1, 2015	'	'
Debentures and Warrants Conversion, Description	'	'	'	'	'The Debenture and the Warrant may not be converted if such conversion would result in Hillair beneficially owning in excess of 4.99% of the Company’s common stock. Hillair may waive this 4.99% restriction with 61 days’ notice to the Company.	'	'
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	'	'	'	1,871,117	'	'	'
Debt Conversion, Original Debt, Amount	'	'	127,857	'	'	104,000	104,700
Interest Expense, Debt	'	'	'	'	'	$4,000	$4,700
Debt Conversion, Converted Instrument, Shares Issued	'	'	127,857	'	'	104,000	104,700

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Aug. 12, 2011

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

21-May-12

Sep. 30, 2014

Dec. 31, 2013

Mortgage payable [Member]

Note Payable GE Capital Construction MRI [Member]

Note Payable GE Capital Construction 2 [Member]

Note Payable, GE Capital (MRI) [Member]

Note Payable GE Capital (X-Ray) [Member]

Note Payable GE Arm [Member]

Note Payable Auto [Member]

Capital lease, Equipment [Member]

Debt Instrument [Line Items]

Notes Payable

$9,110,032

$9,679,260

$7,281,526

$7,353,398

$7,550,000

$165,121

$278,287

$59,336

$100,977

$1,307,717

$1,592,278

$153,076

$184,001

$97,756

$114,597

$17,864

$22,211

$29,850

$27,636

$33,511

Less: current portion

-781,162

-743,787

Notes payable, long term portion

$8,328,870

$8,935,473

NOTES_PAYABLE_Details_1

NOTES PAYABLE (Details 1) (USD $)	Sep. 30, 2014
Long-term Debt, Fiscal Year Maturity [Abstract]	'
Three months ended December 31, 2014	$174,559
Year ended December 31, 2015	715,085
Year ended December 31, 2016	7,632,286
Year ended December 31, 2017	523,608
Year ended December 31, 2018 and thereafter	64,494
Total	$9,110,032

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Aug. 22, 2012

Mar. 08, 2013

Sep. 27, 2012

Mar. 08, 2013

Feb. 25, 2013

Jun. 30, 2013

Aug. 12, 2011

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Dec. 31, 2013

29-May-12

Sep. 30, 2014

Dec. 31, 2013

Sep. 24, 2012

21-May-12

Sep. 30, 2014

Dec. 31, 2013

21-May-12

X Ray Equipment [Member]

MRI Equipment [Member]

C-Arm Equipment [Member]

Equipment Capital Lease [Member]

Mortgage payable [Member]

Note Payable GE Capital [Member]

Note Payable GE Capital Construction MRI [Member]

Note Payable GE Capital Construction 2 [Member]

Note Payable Auto [Member]

GE Healthcare Financial Services [Member]

Equipment Finance Lease [Member]

Debt Instrument [Line Items]

Notes Payable

$9,110,032

$9,679,260

$7,550,000

$7,281,526

$7,353,398

$165,121

$278,287

$59,336

$100,977

$29,850

$17,864

$22,211

$2,400,000

Debt Instrument, Interest Rate During Period

6.10%

7.38%

6.99%

Debt Instrument, Periodic Payment

956.45

45,752.61

Debt Instrument, Maturity Date

1-Jun-17

16-Sep-16

30-Jun-17

Interest and Debt Expense

286,723

Capital Lease Obligations

212,389

1,771,390

117,322

2,288,679

Construction Loan

450,000

150,000

Debt Instrument, Periodic Payment, Principal

593

Construction Loan Term

'60 months

'63 months

'35 monthly

Debt Instrument, Interest Rate, Stated Percentage

7.94%

7.39%

Capital Lease Obligations Due In First 3 Months

1,384

11,779

Capital Lease Obligations Due For Remaining Months

$4,300

$4,575

$38,152

$2,388

Debt Instrument, Interest Rate, Effective Percentage

14.00%

Debt Instrument, Term

'30 years

Capital Lease Equipment, Lease Term

'48 monthly

CAPITAL_STOCK_Details_Textual

CAPITAL STOCK (Details Textual) (USD $)	9 Months Ended
CAPITAL STOCK (Details Textual) (USD $)	Sep. 30, 2014	Sep. 30, 2013
Capital Stock [Line Items]	'	'
Share-Based Compensation	$137,001	$155,875
Stock Issued During Period, Value, Issued For Services	360,341	'
Future Services [Member]	'	'
Capital Stock [Line Items]	'	'
Debt Conversion, Original Debt, Amount	98,000	0
Convertible Notes Payable [Member]	'	'
Capital Stock [Line Items]	'	'
Debt Conversion, Original Debt, Amount	336,557	0
Line of Credit [Member]	'	'
Capital Stock [Line Items]	'	'
Debt Conversion, Original Debt, Amount	150,000	0
Common Stock [Member]	'	'
Capital Stock [Line Items]	'	'
Stock Issued During Period, Shares, Issued For Services	375,000	'
Stock Issued During Period, Value, Issued For Services	375	'
Common Stock [Member] \| Future Services [Member]	'	'
Capital Stock [Line Items]	'	'
Share-Based Compensation	12,250	'
Stock Issued During Period, Shares, Issued For Services	100,000	'
Stock Issued During Period, Value, Issued For Services	$98,000	'
Common Stock [Member] \| Line of Credit [Member]	'	'
Capital Stock [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	200,000	'
Common Stock [Member] \| Employee Incentives [Member]	'	'
Capital Stock [Line Items]	'	'
Stock Issued During Period, Shares, Issued For Services	130,000	'
Common Stock [Member] \| Consulting Services [Member]	'	'
Capital Stock [Line Items]	'	'
Stock Issued During Period, Shares, Issued For Services	175,000	'

STOCK_OPTIONS_AND_WARRANTS_Det

STOCK OPTIONS AND WARRANTS (Details) (Non Employees [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
	Warrant One [Member]	Warrant Two [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Warrants Outstanding, Prices	$1.35	$3.60	'	'	'
Warrants Outstanding	2,320,000	1,875,000	4,195,000	4,195,000	1,875,000
Warrants Outstanding, Expiration Date	8-Nov-18	31-Dec-16	'	'	'
Warrants Outstanding, Weighted Price	$1.35	$3.60	$2.36	$2.36	$3.60
Warrants Exercisable	2,320,000	1,875,000	4,195,000	'	'
Warrants Exercisable, Weighted Price	$1.35	$3.60	$2.36	'	'

STOCK_OPTIONS_AND_WARRANTS_Det1

STOCK OPTIONS AND WARRANTS (Details 1) (Non Employees [Member], Warrant [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Non Employees [Member] \| Warrant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Number of Shares, Outstanding	4,195,000	1,875,000
Number of Shares, Granted	0	2,320,000
Number of Shares, Exercised	0	0
Number of Shares, Expired	0	0
Number of Shares, Outstanding	4,195,000	4,195,000
Weighted Average Price Per Share, Outstanding	$2.36	$3.60
Weighted Average Price Per Share, Granted	$0	$1.35
Weighted Average Price Per Share, Exercised	$0	$0
Weighted Average Price Per Share, Expired	$0	$0
Weighted Average Price Per Share, Outstanding	$2.36	$2.36

SEGMENT_REPORTING_Details

SEGMENT REPORTING (Details) (USD $)	3 Months Ended		9 Months Ended
SEGMENT REPORTING (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue:	'	'	'	'	'
Net Patient Service Revenue	$1,917,597	$1,395,610	$5,814,140	$3,739,435	'
Rental revenue	263,888	259,120	784,534	786,546	'
Total Revenue	1,891,045	1,654,730	6,232,962	4,525,981	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	925,513	735,888	3,081,840	2,000,436	'
Other operating expenses	407,699	353,034	1,264,046	965,923	'
General and administrative	548,635	298,566	1,623,755	898,910	'
Depreciation and amortization	150,084	124,378	411,575	373,803	'
Total operating expenses	2,031,931	1,511,866	6,381,216	4,239,072	'
Net income (loss) from operations:	-140,886	142,864	-148,254	286,909	'
Interest expense	-214,798	-302,590	-651,228	-983,966	'
Amortization of financing costs	-20,686	-22,802	-62,058	-51,477	'
Gain on change in derivative liability	0	-1,631	0	187,351	'
Other income (expense)	750	750	2,250	2,313	'
Net Income (loss):	-375,620	-183,409	-859,290	-558,870	'
Income taxes	0	0	0	0	'
Net income (loss)	-375,620	-183,409	-859,290	-558,870	'
Assets:	'	'	'	'	'
Assets	11,933,826	'	11,933,826	'	11,813,297
Assets acquired	'	'	'	'	'
Property, Plant and Equipment, Additions	57,663	54,255	145,645	319,762	'
Marina Towers [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	373,200	365,839	1,110,171	1,104,405	'
Total Revenue	373,200	365,839	1,110,171	1,104,405	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	3,000	3,000	9,000	9,000	'
Other operating expenses	112,407	95,689	326,008	289,765	'
General and administrative	22,067	21,791	65,789	61,132	'
Depreciation and amortization	69,219	41,571	207,447	123,313	'
Total operating expenses	206,693	162,051	608,244	483,210	'
Net income (loss) from operations:	166,507	203,788	501,927	621,195	'
Interest expense	-113,689	-115,241	-339,780	-347,406	'
Amortization of financing costs	-14,337	-14,337	-43,011	-43,011	'
Gain on change in derivative liability	'	0	'	0	'
Other income (expense)	750	750	2,250	2,313	'
Net Income (loss):	39,231	74,960	121,386	233,091	'
Income taxes	0	0	0	0	'
Net income (loss)	39,231	74,960	121,386	233,091	'
Assets:	'	'	'	'	'
Assets	6,688,386	'	6,688,386	'	6,873,839
Assets acquired	'	'	'	'	'
Property, Plant and Equipment, Additions	0	0	16,758	67,192	'
FCID Medical [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	1,627,157	1,395,610	5,448,428	3,739,435	'
Rental revenue	0	0	0	0	'
Total Revenue	1,627,157	1,395,610	5,448,428	3,739,435	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	834,406	574,487	2,810,844	1,583,238	'
Other operating expenses	404,604	357,696	1,263,675	994,017	'
General and administrative	283,949	140,039	849,110	447,023	'
Depreciation and amortization	66,540	82,807	189,803	250,490	'
Total operating expenses	1,589,499	1,155,029	5,113,432	3,274,768	'
Net income (loss) from operations:	37,658	240,581	334,996	464,667	'
Interest expense	-56,162	-78,039	-171,450	-208,773	'
Amortization of financing costs	-6,349	-8,465	-19,047	-8,466	'
Gain on change in derivative liability	'	0	'	0	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	-24,853	154,077	144,499	247,428	'
Income taxes	0	0	0	0	'
Net income (loss)	-24,853	154,077	144,499	247,428	'
Assets:	'	'	'	'	'
Assets	4,837,380	'	4,837,380	'	4,178,091
Assets acquired	'	'	'	'	'
Property, Plant and Equipment, Additions	57,663	54,255	128,887	252,570	'
Corporate [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	0	0	0	0	'
Total Revenue	0	0	0	0	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	88,107	158,401	261,996	408,198	'
Other operating expenses	0	0	0	0	'
General and administrative	242,619	136,736	708,856	390,755	'
Depreciation and amortization	14,325	0	14,325	0	'
Total operating expenses	345,051	295,137	985,177	798,953	'
Net income (loss) from operations:	-345,051	-295,137	-985,177	-798,953	'
Interest expense	-44,947	-109,310	-139,998	-427,787	'
Amortization of financing costs	0	0	0	0	'
Gain on change in derivative liability	'	-1,631	'	187,351	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	-389,998	-406,078	-1,125,175	-1,039,389	'
Income taxes	0	0	0	0	'
Net income (loss)	-389,998	-406,078	-1,125,175	-1,039,389	'
Assets:	'	'	'	'	'
Assets	408,060	'	408,060	'	761,367
Assets acquired	'	'	'	'	'
Property, Plant and Equipment, Additions	0	0	0	0	'
Intercompany Eliminations [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Net Patient Service Revenue	0	0	0	0	'
Rental revenue	-109,312	-106,719	-325,637	-317,859	'
Total Revenue	-109,312	-106,719	-325,637	-317,859	'
Operating expenses:	'	'	'	'	'
Salaries & benefits	0	0	0	0	'
Other operating expenses	-109,312	-100,351	-325,637	-317,859	'
General and administrative	0	0	0	0	'
Depreciation and amortization	0	0	0	0	'
Total operating expenses	-109,312	-100,351	-325,637	-317,859	'
Net income (loss) from operations:	0	-6,368	0	0	'
Interest expense	0	0	0	0	'
Amortization of financing costs	0	0	0	0	'
Gain on change in derivative liability	'	0	'	0	'
Other income (expense)	0	0	0	0	'
Net Income (loss):	0	-6,368	0	0	'
Income taxes	0	0	0	0	'
Net income (loss)	0	-6,368	0	0	'
Assets:	'	'	'	'	'
Assets	0	'	0	'	0
Assets acquired	'	'	'	'	'
Property, Plant and Equipment, Additions	$0	$0	$0	$0	'

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	9 Months Ended
SUBSEQUENT EVENTS (Details Textual) (USD $)	Sep. 30, 2014
Subsequent Event [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	'vest in two (2) equal annual installments on the first and second anniversaries of his employment.
Marina Towers Holdings, LLC [Member]	'
Subsequent Event [Line Items]	'
Stock Issued During Period, Shares, for Gift	1,800,000
Church Organization [Member]	'
Subsequent Event [Line Items]	'
Number of Shares in Transaction	100,000
Beneficiary [Member]	'
Subsequent Event [Line Items]	'
Number of Shares in Transaction	1,700,000
Chief Executive Officer [Member]	'
Subsequent Event [Line Items]	'
Stock Issued During Period, Shares, New Issues	50,000
Number of Shares in Transaction	5,750,000
Chief Executive Officer [Member] \| Employee Relocation [Member]	'
Subsequent Event [Line Items]	'
Relocation Expenses	6,000